DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages

Benign lymphoplasmacytic plaque

Author: Dr Moushumi Das, Medical Registrar, Waikato Hospital, Hamilton, New Zealand; Chief Editor: A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, February 2016.

Benign lymphoplasmacytic plaque — codes and concepts

What is benign lymphoplasmacytic plaque?

Benign lymphoplasmacytic plaque was first described in 2009, with few reported cases. It is defined by one or more chronic skin lesions, either solitary or in clusters, that have characteristic dense lymphocytic and polyclonal plasma cell infiltrates on biopsy

Benign lymphoplasmacytic plaque has also been called cutaneous lymphoplasmacytic lymphoma and pretibial lymphoplasmacytic plaque.

Who gets benign lymphoplasmacytic plaque?

Benign lymphoplasmacytic plaque has mostly been reported to affect female children between the ages of 7 and 15. Isolated cases have been described in adult males over the age of 60. It seems to predominantly affect people of Caucasian descent, although cases have also been described in Japanese, African and South Asian (Indian) children. 

What causes benign lymphoplasmacytic plaque?

The cause of benign lymphoplasmacytic plaque is unknown. Preceding trauma to the affected area has been noted in a few cases, but no direct correlation has been confirmed.

What are the clinical features of benign lymphoplasmacytic plaque?

Benign lymphoplasmacytic plaque presents as a solitary chronic, persistent and asymptomatic skin lesion that is resistant to topical and systemic treatment.  Clusters of similar lesions may occur.

    • The mean duration is 3 years.
    • The lesion is a variable, reddish-brown, painless papule or a scaly plaque.
    • They most often affect the lower legs, but may also arise on upper limbs and buttocks.
    • There are usually no other lesions elsewhere, and there are no systemic symptoms.
Lymphoplasmacytic plaque

How is benign lymphoplasmacytic plaque diagnosed?

The diagnosis of benign lymphoplasmacytic plaque is made by dermatopathology and clinicopathologic correlation. The defining, compulsory histological findings are:

  • Dense lymphohistiocytic infiltrate
  • The presence of large numbers of plasma cells
  • The absence of clonality of plasma cells
  • No atypical cells in the infiltrate.

Other tests should be performed to rule out infections, specifically atypical mycobacteria, leishmaniasis, borreliosis, syphilis and fungal infections. The plasma cells must be tested for clonality to exclude the possibility of a lymphoproliferative disorder.

What is the treatment for benign lymphoplasmacytic plaque?

Benign lymphoplasmacytic plaque can be removed by surgical excision. Topical steroids and systemic steroids, intralesional steroid injection, partial removal by shave excision, and oral antibiotics have not proved successful. 

What is the outcome for benign lymphoplasmacytic plaque?

It is uncertain how benign lymphoplasmacytic plaque progresses long term. 

See smartphone apps to check your skin.
[Sponsored content]


Related information



  • Mitteldorf C, Palmedo G, Kutzner H, Kauer F, Prestin M, Schuster C, Hübscher E et. al. Diagnostic approach in lymphoplasmacytic plaque. J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2206-15. PubMed.
  • Porto DA, Sutton S, Wilson JB, Scupham RK, Stone MS, Liu V Lymphoplasmacytic plaque in children: a report of two cases with review of the literature J Cutan Pathol 2013: 40: 50–55. PubMed.
  • Gillam A, Renata H, Oviedo G, Bhatnagar R, Smith MK, Patton DF et. al. Isolated benign primary cutaneous plasmacytosis in children: two illustrive cases. Arch Dermatol. 2009 March ; 145(3): 299–302. PubMed.

On DermNet NZ

Books about skin diseases

See the DermNet NZ bookstore.